New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

34

U.S. FDA Approves Second Indication for Skyrizi to Treat Adults with Active Psoriatic Arthritis

The U.S. Food and Drug Administration approved AbbVie’s Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts 30 percent of patients with psoriasis.

35

U.S. studies highlight the need for COVID boosters to fight Omicron

Three U.S. studies show that a third dose of an mRNA vaccine is key to fighting the Omicron coronavirus variant, providing 90% protection against hospitalization due to COVID-19, the U.S. Centers for Disease Control and Prevention (CDC) said on January 21.

39

BIO Report Outlines Economic Impact of Booming Life Sciences Industry

The Biotechnology Innovation Organization (BIO) provides a glimpse of economic development in the biosciences ecosystem at the state and regional levels. The report, which was developed in partnership with the Council of State Bioscience Associations (CSBA), was released as an industry analysis in the wake of the COVID-19 pandemic and its impact on the overall economy. 

40

Small children getting less sick from Omicron; Genetic mutation protects against severe COVID

In very young children, the Omicron variant of the coronavirus causes less severe disease than the Delta variant, according to a new study. In other research, new findings add to evidence that people with a certain version of a gene are less likely to develop severe COVID-19.